biopharma-reporter5h
Sarepta discontinues development of Duchenne ASO treatment vesleteplirsen
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...
biopharma-reporter9h
Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases
The two companies have formed Oblenio Bio to develop a tri-specific T-cell engager The U.S. company Aditum Bio and Chinese ...
biopharma-reporter2d
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
biopharma-reporter2d
Synaffix and BigHat Biosciences collaborate to develop AI-designed ADC
The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they have entered into a ...
biopharma-reporter6d
Top 10 rare disease pharma sees 10.4% rise in therapy start
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% ...
biopharma-reporter6d
Abzena’s advanced drug development showcased at CPHI Milan
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the ...